Avalo Therapeutics News

Avalo Therapeutics Analyst Ratings

BenzingaApr 16 08:51 ET

RBC Capital Downgrades Avalo Therapeutics to Sector Perform, Lowers Price Target to $0.75

BenzingaJun 27, 2023 07:42 ET

Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept

MT NewswiresJun 27, 2023 07:16 ET

RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier

MT NewswiresMay 10, 2023 07:51 ET

Jefferies Downgrades Avalo Therapeutics to Underperform, Announces $3 Price Target

Benzinga Real-time NewsFeb 8, 2023 08:18 ET

Avalo Therapeutics Analyst Ratings

Benzinga Analyst RatingsFeb 8, 2023 08:14 ET

Avalo Therapeutics (AVTX) Gets a Buy From RBC Capital

TipRanksNov 10, 2022 20:55 ET

Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating

MT NewswiresAug 8, 2022 10:47 ET

RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier

MT NewswiresAug 5, 2022 07:52 ET

RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept

MT NewswiresJul 11, 2022 08:48 ET